Rubriik: Uudised

Dimitri Poffé dokumentaalfilm "The Present" on nüüd saadaval Youtube'is

Dimitri Poffé is an already known member of the HD Community. After testing positive for Huntington’s Disease, Dimitri embraced a bicycle journey through South America. In this project, called Explore […]

PTC Therapeutics sõlmib ülemaailmse litsentsi- ja koostöölepingu Novartisiga PTC518 Huntingtoni tõve programmi jaoks

December 2, 2024 – PTC to receive $1.0B in cash at closing –– PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones –– PTC to share profits in the U.S. and […]

Sage Therapeutics lõpetab dalzanemdor'i arendamise HD puhul

The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan […]

Partnerluse jõud. Šveits ja Hiina on eeskujuks.

In this video, Professor Jean-Marc Burgunder, head of the Huntington’s Disease (HD) centre in Bern Switzerland, and Xi Cao, President of the Chinese HD Association talk about the benefits of […]

Elamisväärsed elud - uus raamat, mis toob esile HD poolt mõjutatud inimeste lugusid kogu maailmas.

PRESSITEADE - 25. oktoober 2024, Moskva, Idaho, USAMeil on hea meel teatada uue Huntingtoni tõve (HD) kohta käiva raamatu "Elamisväärsed elud" ilmumisest: Conversations with the Huntington's [...]

LoQus23 Therapeutics teatab 35 miljoni naelsterlingi suurusest rahastamisest, et arendada uut ravimit, mille eesmärk on pärssida somaatilist laienemist Huntingtoni tõve korral.

Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy […]

FDA annab PTC518 Huntingtoni tõve programmile kiireloomulise nimetuse

PTC518 is an oral medication that reduces the production of the mutated Huntingtin protein that causes disease progression.   Programs with Fast Track designation can benefit from early interactions with the FDA, and may be […]

Prilenia's Pridopidine's Huntingtoni tõve raviks on heaks kiidetud Euroopa müügiloa läbivaatamine

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing […]

IROS, Prilenia ja Rahvusvaheline Huntingtoni tõve ühing teevad koostööd esimese Huntingtoni tõve (HD) uuringu läbiviimiseks MENA piirkonnas.

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International […]

uniQure annab teada positiivsetest vahepealsetest andmetest, mis näitavad haiguse progresseerumise aeglustumist AMT-130 faasi I/II uuringutes HD raviks.

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” […]